Pfizer and Moderna refuse to cooperate with Johnson & Johnson on coagulation of the new crown vaccine

CompileKe Ke

According to a recent report by the Wall Street Journal, Johnson & Johnson contacted Pfizer, Moderna and AstraZeneca to ask them to investigate the coagulation problem caused by the COVID-19 vaccine and "express opinions on safety issues.

The two pharmaceutical companies believe that there is no need to repeat the investigation of the drug regulatory agency.

So far, AstraZeneca/Oxford University and Johnson & Johnson's COVID-19 vaccine products are all related to a very rare but potentially life-threatening blood clotting problem, but the real cause of blood clotting has not yet been determined.

In addition, the blood problems associated with each vaccine are not the same.

For Johnson & Johnson's vaccine, the coagulation problem is manifested by cerebral venous sinus thrombosis (CVST), which is observed with low levels of platelets (thrombocytopenia).

In the AstraZeneca/Oxford University vaccine case, the reported thrombosis problems were deep vein thrombosis (DVT) and pulmonary embolism.

Prior to this, AstraZeneca had agreed to cooperate with Johnson & Johnson.

A Johnson & Johnson spokesperson pointed out that the company believes that cooperation can help answer questions about thrombosis and patient safety.

In the Johnson & Johnson study, the risk of blood clots is about one in a million, while the risk of blood clots caused by the AstraZeneca vaccine is about five in a million.

Paul Harrison, professor of psychiatry at the University of Oxford and head of the Translational Neurobiology Group, said: "COVID-19 has significantly increased the risk of CVT and increased blood clotting problems caused by this infection.

Although Moderna and Pfizer/BioNTech’s mRNA vaccines use lipid nanoparticles to deliver mRNA encoding the spike protein of the COVID-19 virus, AstraZeneca/Oxford University and Johnson & Johnson vaccines both use common cold adenovirus as a carrier; Johnson & Johnson vaccine uses human adenovirus , While the AstraZeneca/Oxford vaccine uses chimpanzee adenovirus.

There is still some controversy as to whether this "excessive caution" on the risk of coagulation is really "excessive caution".

Kawsar Talaat, an assistant professor in the Department of International Health at the Bloomberg School of Public Health at Johns Hopkins University, believes: "This may discourage people from vaccination, but what needs to be considered is that this is a new vaccine.

Reference source: J&J Wanted to Collab on Blood Clotting Investigation, but Pfizer and Moderna Declined